|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial显示文摘AIM To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic parameters of nonalcoholic steatohepatitis(NASH).METHODS Twelve patients with biopsy-proven NASH were randomized to sitagliptin(100 mg daily)(n=6)or placebo(n=6)for 24 wk.The primary outcome was improvement in liver fibrosis after 24 wk.Secondary outcomes included evaluation of changes in NAFLD activity score(NAS),individual components of NAS(hepatocyte ballooning,lobular inflammation,and steatosis),glycemic control and insulin resistance[including measurements of glycated hemoglobin(Hb A1C)and adipocytokines],lipid profile including free fatty acids,adipose distribution measured using magnetic resonance imaging(MRI),and thrombosis markers(platelet aggregation and plasminogen activator inhibitor 1 levels).We also sought to determine the correlation between changes in hepatic fat fraction(%)[as measured using the Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares estimation(IDEAL)MRI technique]and changes in hepatic steatosis on liver biopsy.RESULTS Sitagliptin was not significantly better than placebo at reducing liver fibrosis score as measured on liver biopsy(mean difference between sitagliptin and placebo arms,0.40,P=0.82).There were no significant improvements evident with the use of sitagliptin vs placebo for the secondary histologic outcomes of NAS total score as well as for the individual components of NAS.Compared to baseline,those patients who received sitagliptin demonstrated improved Hb A1C(6.7%±0.4%vs 7.9%±1.0%,P=0.02),and trended towards improved adiponectin levels(4.7±3.5μg/m L vs 3.9±2.7μg/m L,P=0.06)and triglyceride levels(1.26±0.43 mmol/L vs 2.80±1.64 mmol/L,P=0.08).However,when compared with placebo,sitagliptin did not cause a statistically significant improvement in Hb A1C(mean difference,-0.7%,P=0.19)nor triglyceride levels(mean difference-1.10mmol/L,P=0.19)but did trend towards improved adiponectin levels only(mean difference,0.60μg/m L,P=0.095).No significant changes in anthropometrics,liver enzymes,other adipocytokines,lipid profile,thrombosis parameters,or adipose distribution were demonstrated.The MRI IDEAL procedure correlated well with steatosis scores obtained on liver biopsy in both groups at baseline and post-treatment,and the Spearman correlation coefficients ranged from r=0.819(baseline)to r=0.878(post-treatment),P=0.002.CONCLUSION Sitagliptin does not improve fibrosis score or NAS after 24 wk of therapy.The MRI IDEAL technique may be useful for non-invasive measurement of hepatic steatosis. | Tisha R Joy Charles A McKenzie Rommel G Tirona Kelly Summers Shannon Seney Subrata Chakrabarti Neel Malhotra Melanie D Beaton | 2017 | World Journal of Gastroenterology2017，23，1： | 18 |
| 2 | Management of non-alcoholic fatty liver disease in 2015显示文摘There is no single pharmacologic therapy that has been approved to treat nonalcoholic fatty liver disease in the general population. The backbone of therapy currently includes intensive lifestyle modification withestablished targets for diet and weight loss. The use of unsweetened, unfiltered coffee along with limiting high fructose corn syrup have emerged as beneficial dietary recommendations. The use of empiric oral hypoglycemic agents and vitamin E, however, has not been widely accepted. Developing bariatric surgical techniques are promising, but additional studies with long-term follow up are needed before it can be widely recommended. Finally, liver transplantation is an increasingly frequent consideration once complications of endstage disease have developed. The future treatment of those with nonalcoholic fatty liver disease will likely involve a personalized approach. The importance of the gut microbiome in mediating hepatocyte inflammation and intestinal permeability is emerging and may offer avenues for novel treatment. The study of anti-fibrotic agents such as pentoxifylline and FXR agonists hold promise and new pathways, such as hepatocyte cannabinoid receptor antagonists are being studied. With the incidence of obesity and the metabolic syndrome increasing throughout the developed world, the future will continue to focus on finding novel agents and new applications of existing therapies to help prevent and to mediate the progression of nonalcoholic fatty liver disease. | Neel Malhotra Melanie D Beaton | 2015 | World Journal of Hepatology2015，7，30： | 6 |
| 3 | Outcomes of submucosal(T1b) esophageal adenocarcinomas removed by endoscopic mucosal resection显示文摘AIM To investigate the outcomes and recurrences of p T1 b esophageal adenocarcinoma(EAC) following endoscopic mucosal resection(EMR) and associated treatments.METHODS Patients undergoing EMR with pathologically confirmed T1 b EAC at two academic referral centers were retrospectively identified.Patients were divided into 4 groups based on treatment following EMR:Endoscopic therapy alone(group A),endoscopic therapy with either chemotherapy,radiation or both(group B),surgicalresection(group C) or no further treatment/lost to follow-up(<12 mo)(group D).Pathology specimens were reviewed by a central pathologist.Follow-up data was obtained from the academic centers,primary care physicians and/or referring physicians.Univariate analysis was performed to identify factors predicting recurrence of EAC.RESULTS Fifty-three patients with T1 b EAC underwent EMR,of which 32(60%) had adequate follow-up ≥ 12 mo(median 34 mo,range 12-103).There were 16 patients in group A,9 in group B,7 in group C and 21 in group D.Median follow-up in groups A to C was 34 mo(range 12-103).Recurrent EAC developed overall in 9 patients(28%) including 6(38%) in group A(median:21 mo,range:6-73),1(11%) in group B(median:30 mo,range:30-30) and 2(29%) in group C(median 21 mo,range:7-35.Six of 9 recurrences were local;of the 6 recurrences,5 were treated with endoscopy alone.No predictors of recurrence of EAC were identified.CONCLUSION Endoscopic therapy of T1 b EAC may be a reasonable strategy for a subset of patients including those either refusing or medically unfit for esophagectomy. | Darren D Ballard Neel Choksi Jingmei Lin Eun-Young Choi B Joseph Elmunzer Henry Appelman Douglas K Rex Hala Fatima William Kessler John M DeWitt | 2016 | World Journal of Gastrointestinal Endoscopy2016，8，20： | 2 |
| 4 | IL 28 B genotype is not useful for predicting treatment outcome in A sian chronic hepatitis B patients treated with pegylated interferon‐α显示文摘 | Jacinta A Holmes Tin Nguyen Dilip Ratnam Neel M Heerasing Jane V Tehan Sara Bonanzinga Anouk Dev Sally Bell Stephen Pianko Robert Chen Kumar Visvanathan Rachel Hammond David Iser Ferry Rusli William Sievert Paul V Desmond D Scott Bowden Alexander J Thomps | 2013 | J Gastroenterol Hepatol2013，，5： | 2 |
| 5 | Exposure of the Flemish population to brominated flame retardants: Model and risk assessment显示文摘 | Laurence Roosens Christa Cornelis Wendy D’Hollander Lieven Bervoets Hans Reynders Karen Van Campenhout Rosette Van Den Heuvel Hugo Neels Adrian Covaci | 2010 | Environment International2010，，4： | 1 |
| 6 | Does Mandatory Adop- tion of IFRS Improve Accounting Quality? Preliminary Evidence 显示文摘 | Ahmed A S Neel M Wang D | 2013 | Contemporary Accounting Research2013，30，04： | 1 |
| 7 | Tree seedling growth : effects of shaking显示文摘 | Parkhurst D F Pearman G I Neel P L | 1972 | Science1972，175，： | 1 |
| 8 | The lyrosine phosphatase Shp2 (PTPN11)in cancer 显示文摘 | Chan G Kalaitzidis D Neel BG | 2008 | Cancer Metastasis Rev2008，27，2： | 1 |
| 9 | Chloroplast DNA diversity in populations of wild and cultivated barley显示文摘 | Neele D B Saghai M A Allard R W | 1988 | Genetics1988，120，： | 1 |
| 10 | Early glottic carcinoma treated with open laryngeal procedures 显示文摘 | Thomas J V Olsen K D Neel H B | 1994 | Arch Otolaryngol Head Neck Surg1994，120，： | 1 |
| 11 | The tyrosine phosphatase Shp2 (PTPN 11) in eancer显示文摘 | Chan G Kalaitzidis D Neel B G | 2008 | Cancer Metaslasis Rev2008，27，2： | 1 |
| 12 | Fractional diffusion and reflective boundary condition显示文摘 | KREPYSHEVA N PIETRO L D NEEL M C | 2006 | Physica A2006，368，： | 1 |
| 13 | The tyrosine phosphatase Shp2(PTPN11) in cancer显示文摘 | Chan G Kalaitzidis D Neel BG | 2008 | Cancer Metastasis Rev2008，27，2： | 1 |
| 14 | Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation显示文摘 | Matin T.M Keith K Davies B Conner D.A Guha P Kalaitzidis D Wu X Lauriol J Wang B Bauer M Bronson R Franchini K.G Neel B.G Kontaridis M.I | | 0，，： | 1 |
| 15 | The tyrosine phosphatase Shp2 (PTPN11) in cancer 显示文摘 | Chan G Kalaitzidis D Neel B G | 2008 | Cancer and metastasis reviews2008，27，2： | 1 |
| 16 | Near Shannon limit performance of low density parity cheek codes 显示文摘 | Mackay D J C Neel R M | 1996 | Electronic Letters1996，32，18： | 1 |
| 17 | Recuperation des COV par permeation de vapour: brat de la technique et perspectives显示文摘 | Favre E Tondeur D Neel J | 1995 | Inform Chimie1995，372，： | 1 |
| 18 | Modeling Asymmetric Volatility in Weekly Dutch Temperature Data显示文摘 | Franses P H Neele J Dijk D V | 2001 | Environmental Modelling & Software2001，，2： | 1 |
| 19 | Glucocorticoids and thiazolidinediones interfere with adipocyte-mediated macrophage chemotaxis and recruitment显示文摘 | Patsouris D Neels JG Fan WQ | 2009 | J Biol Chem2009，284，31： | 1 |
| 20 | The cholesterol content of HDL2 and HDL3 subfraction of HDL in different normal cholesterolernic population 显示文摘 | Neel D Beaudry P Erlich D | 1984 | Chem Acta1984，，142： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员